DRD2 and central nervous system cancer: Dopamine and its receptor (DRD1–3) are also neurotransmitters that have been associated with increased endometrial cancer severity and reduced progression-free survival [60], with the DRD2 antagonist ONC201 shown to reduce tumour growth in vivo [61], including the highly aggressive H3K27M mutant gliomas [62].